Recent studies have detailed the genomic landscape of primary endometrial cancers, but
the evolution of these cancers into metastases has not been characterized. We performed …

Introduction: Lung cancer is the leading cause of cancer-related mortality globally. Despite
recent advances with personalized therapies and immunotherapy, the prognosis remains …

Clinical oncology is advancing toward a more personalized treatment orientation, making
the need to understand the biology of metastasis increasingly acute. Dissecting the complex …

SCLC is an aggressive form of lung cancer with a very poor prognosis. Although SCLC
initially responds very well to platinum-based chemotherapy, it eventually recurs and at …

Purpose: The optimal systemic treatment for pulmonary large-cell neuroendocrine
carcinoma (LCNEC) is still under debate. Previous studies showed that LCNEC with …

The development of genetic engineering in the 1970s marked a new frontier in genome-
editing technology. Gene-editing technologies have provided a plethora of benefits to the life …

Purpose: Small-cell lung cancer (SCLC) is an often-fatal neuroendocrine carcinoma usually
presenting as extensive disease, carrying a 3% 5-year survival. Despite notable advances in …

Mouse models of cancers are routinely used to study cancer biology. However, it remains
unclear whether carcinogenesis in mice is driven by the same spectrum of genomic …

Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor, and no effective
treatment is available to date. Mouse models of SCLC based on the inactivation of Rb1 and …

Using unbiased kinase profiling, we identified protein kinase A (PKA) as an active kinase in
small cell lung cancer (SCLC). Inhibition of PKA activity genetically, or pharmacologically by …